While Ikena Oncology Inc has underperformed by -9.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IKNA fell by -21.34%, with highs and lows ranging from $1.94 to $0.97, whereas the simple moving average fell by -11.04% in the last 200 days.
On May 29, 2024, Wedbush Downgraded Ikena Oncology Inc (NASDAQ: IKNA) to Neutral. A report published by Wedbush on September 22, 2023, Initiated its previous ‘Outperform’ rating for IKNA. H.C. Wainwright also rated IKNA shares as ‘Buy’, setting a target price of $18 on the company’s shares in an initiating report dated May 04, 2023. H.C. Wainwright Initiated an Buy rating on December 23, 2021, and assigned a price target of $25. Credit Suisse initiated its ‘Outperform’ rating for IKNA, as published in its report on May 05, 2021. Credit Suisse’s report from April 26, 2021 suggests a price prediction of $30 for IKNA shares, giving the stock a ‘Outperform’ rating. William Blair also rated the stock as ‘Outperform’.
Analysis of Ikena Oncology Inc (IKNA)
Ikena Oncology Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -30.49% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 13.31, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and IKNA is registering an average volume of 132.89K. On a monthly basis, the volatility of the stock is set at 4.43%, whereas on a weekly basis, it is put at 7.28%, with a loss of -3.73% over the past seven days. Furthermore, long-term investors anticipate a median target price of $2.00, showing growth from the present price of $1.29, which can serve as yet another indication of whether IKNA is worth investing in or should be passed over.
How Do You Analyze Ikena Oncology Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 56.58%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 33.21% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IKNA shares are owned by institutional investors to the tune of 33.21% at present.
